Enliven Therapeutics (ELVN)
Enliven Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
9.3M
Short interest
settlement 2026-10-15
7.5
Days to cover
+2.0 days vs prior
74.2%
Short share of volume
2026-11-02
2,503
Fails to deliver
settlement 2026-10-02
Wed 11 Nov
Next earnings
estimated date
-$2.2M
Insider flow, 90 days
0 buys, 13 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ELVN is 9,331,398 shares, up 710,895 shares over the last month. Over the last 48 readings it ranged from 4,856,687 shares (15 September 2025) to 10,356,282 shares (30 September 2026). At the reported average volume of 1.3M shares a day that is 7.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/elvn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 9,331,398 | -9.9% | 1,252,969 | 7.45 |
| 2026-09-30 | 10,356,282 | +20.1% | 1,887,497 | 5.49 |
| 2026-09-15 | 8,620,503 | +0.2% | 956,494 | 9.01 |
| 2026-08-31 | 8,600,289 | +4.1% | 776,607 | 11.07 |
| 2026-08-14 | 8,258,991 | +1.3% | 1,304,405 | 6.33 |
| 2026-07-31 | 8,151,554 | -5.8% | 712,367 | 11.44 |
| 2026-07-15 | 8,651,596 | +1.5% | 919,272 | 9.41 |
| 2026-06-30 | 8,527,025 | +57.1% | 2,755,836 | 3.09 |
| 2026-06-15 | 5,426,405 | +4.1% | 2,079,224 | 2.61 |
| 2026-05-29 | 5,213,383 | +1.8% | 597,268 | 8.73 |
| 2026-05-15 | 5,122,350 | -2.9% | 636,686 | 8.05 |
| 2026-04-30 | 5,273,791 | -1.9% | 768,825 | 6.86 |
| 2026-04-15 | 5,374,014 | -11.2% | 1,254,668 | 4.28 |
| 2026-03-31 | 6,053,456 | -26.3% | 2,117,376 | 2.86 |
| 2026-03-13 | 8,215,500 | +3.0% | 779,453 | 10.54 |
| 2026-02-27 | 7,979,674 | -1.2% | 650,975 | 12.26 |
| 2026-02-13 | 8,078,549 | +2.6% | 720,452 | 11.21 |
| 2026-01-30 | 7,870,182 | -14.1% | 997,280 | 7.89 |
| 2026-01-15 | 9,166,736 | +10.3% | 2,190,049 | 4.19 |
| 2025-12-31 | 8,312,949 | +2.5% | 701,388 | 11.85 |
| 2025-12-15 | 8,111,262 | +1.4% | 826,728 | 9.81 |
| 2025-11-28 | 7,996,827 | +2.6% | 542,671 | 14.74 |
| 2025-11-14 | 7,794,126 | +0.1% | 751,520 | 10.37 |
| 2025-10-31 | 7,782,638 | +21.2% | 427,946 | 18.19 |
| 2025-10-15 | 6,422,840 | +12.7% | 413,696 | 15.53 |
| 2025-09-30 | 5,699,585 | +17.4% | 693,643 | 8.22 |
| 2025-09-15 | 4,856,687 | -0.7% | 476,600 | 10.19 |
| 2025-08-29 | 4,891,510 | -1.1% | 475,097 | 10.30 |
| 2025-08-15 | 4,944,385 | -2.6% | 377,257 | 13.11 |
| 2025-07-31 | 5,076,202 | -8.4% | 331,531 | 15.31 |
| 2025-07-15 | 5,543,837 | -9.6% | 556,990 | 9.95 |
| 2025-06-30 | 6,133,570 | -7.4% | 682,189 | 8.99 |
| 2025-06-13 | 6,620,560 | +1.8% | 757,244 | 8.74 |
| 2025-05-30 | 6,503,888 | -0.5% | 293,933 | 22.13 |
| 2025-05-15 | 6,537,096 | -6.1% | 401,324 | 16.29 |
| 2025-04-30 | 6,962,578 | -6.5% | 241,261 | 28.86 |
| 2025-04-15 | 7,442,386 | +2.4% | 416,543 | 17.87 |
| 2025-03-31 | 7,265,725 | -0.9% | 261,051 | 27.83 |
| 2025-03-14 | 7,335,188 | -0.5% | 243,504 | 30.12 |
| 2025-02-28 | 7,375,213 | -0.9% | 143,703 | 51.32 |
| 2025-02-14 | 7,442,501 | +4.7% | 216,755 | 34.34 |
| 2025-01-31 | 7,110,223 | +0.2% | 264,877 | 26.84 |
| 2025-01-15 | 7,096,259 | +2.4% | 265,202 | 26.76 |
| 2024-12-31 | 6,930,336 | +0.8% | 222,119 | 31.20 |
| 2024-12-13 | 6,873,517 | -0.5% | 154,258 | 44.56 |
| 2024-11-29 | 6,908,627 | -2.2% | 191,333 | 36.11 |
| 2024-11-15 | 7,065,704 | +2.3% | 288,595 | 24.48 |
| 2024-10-31 | 6,906,424 | +6.0% | 193,875 | 35.62 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ELVN volume is 74.2%, down 1.7 points over the last five sessions. Over the last 30 readings it ranged from 32.8% (29 October 2026) to 83.2% (23 October 2026). The latest reading is 11.8 points above the 30-session average of 62.4%, on 326K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 242K | 326K | 74.2% | 3,384 |
| 2026-10-30 | 173K | 333K | 52.0% | 0 |
| 2026-10-29 | 103K | 314K | 32.8% | 0 |
| 2026-10-28 | 213K | 288K | 73.9% | 0 |
| 2026-10-27 | 536K | 712K | 75.2% | 0 |
| 2026-10-26 | 351K | 462K | 76.0% | 0 |
| 2026-10-23 | 330K | 397K | 83.2% | 623 |
| 2026-10-22 | 398K | 496K | 80.2% | 0 |
| 2026-10-21 | 384K | 498K | 77.0% | 0 |
| 2026-10-20 | 549K | 751K | 73.1% | 0 |
| 2026-10-19 | 107K | 256K | 41.9% | 5,264 |
| 2026-10-16 | 216K | 467K | 46.3% | 0 |
| 2026-10-15 | 265K | 726K | 36.5% | 0 |
| 2026-10-14 | 250K | 615K | 40.6% | 26,137 |
| 2026-10-13 | 203K | 308K | 65.8% | 1,968 |
| 2026-10-12 | 175K | 242K | 72.4% | 11 |
| 2026-10-09 | 315K | 447K | 70.4% | 0 |
| 2026-10-08 | 389K | 663K | 58.6% | 2,197 |
| 2026-10-07 | 263K | 470K | 55.9% | 51 |
| 2026-10-06 | 569K | 1.0M | 54.3% | 0 |
| 2026-10-05 | 169K | 410K | 41.4% | 0 |
| 2026-10-02 | 220K | 295K | 74.3% | 0 |
| 2026-10-01 | 296K | 390K | 75.8% | 8,579 |
| 2026-09-30 | 142K | 232K | 61.1% | 0 |
| 2026-09-29 | 378K | 738K | 51.3% | 0 |
| 2026-09-28 | 463K | 567K | 81.7% | 0 |
| 2026-09-25 | 333K | 493K | 67.5% | 35,698 |
| 2026-09-24 | 274K | 387K | 70.8% | 0 |
| 2026-09-23 | 299K | 701K | 42.6% | 1,046 |
| 2026-09-22 | 369K | 560K | 66.0% | 1,429 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 2 October 2026, the fails-to-deliver balance in ELVN is 2,503 shares, up 2,502 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (23 September 2026) to 39,831 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-02 | 2,503 | $46.21 | $116K |
| 2026-09-23 | 1 | $48.19 | $48 |
| 2026-09-11 | 31 | $56.23 | $2K |
| 2026-09-10 | 28,913 | $57.45 | $1.7M |
| 2026-08-11 | 1,426 | $59.42 | $85K |
| 2026-07-30 | 8 | $52.97 | $424 |
| 2026-07-27 | 990 | $52.95 | $52K |
| 2026-07-24 | 200 | $52.81 | $11K |
| 2026-07-23 | 200 | $52.85 | $11K |
| 2026-07-22 | 200 | $54.33 | $11K |
| 2026-07-15 | 44 | $51.73 | $2K |
| 2026-07-14 | 402 | $50.87 | $20K |
| 2026-07-10 | 8 | $52.18 | $417 |
| 2026-07-02 | 89 | $48.76 | $4K |
| 2026-07-01 | 11 | $50.75 | $558 |
| 2026-06-30 | 39,831 | $50.85 | $2.0M |
| 2026-06-18 | 146 | $44.86 | $7K |
| 2026-06-09 | 33,071 | $33.63 | $1.1M |
| 2026-06-05 | 31,591 | $35.49 | $1.1M |
| 2026-06-04 | 6,633 | $36.03 | $239K |
| 2026-06-02 | 14 | $37.51 | $525 |
| 2026-05-19 | 607 | $39.63 | $24K |
| 2026-05-14 | 10,394 | $43.56 | $453K |
| 2026-04-20 | 367 | $48.11 | $18K |
| 2026-04-13 | 55 | $45.32 | $2K |
| 2026-04-06 | 15,603 | $38.83 | $606K |
| 2026-04-02 | 15,707 | $37.79 | $594K |
| 2026-03-31 | 1,079 | $36.59 | $39K |
| 2026-03-30 | 18 | $38.83 | $699 |
| 2026-03-19 | 43 | $27.25 | $1K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ELVN reported 13 open-market sells worth $2.2M in the last 90 days and no open-market buys. Latest filing: Collins Helen Louise (CHIEF MEDICAL OFFICER) on 2026-10-19.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 5K | $38.47 | $192K | 25K |
| 2026-10-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 5K | $2.48 | $12K | 30K |
| 2026-10-19 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 6K | $38.48 | $232K | 38K |
| 2026-10-19 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Exercise or conversion | 6K | $14.85 | $89K | 44K |
| 2026-10-01 | Garland J. Scott | Director | Sell | 13K | $46.67 | $607K | 0 |
| 2026-10-01 | Garland J. Scott | Director | Exercise or conversion | 13K | $15.47 | $201K | 13K |
| 2026-09-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 240 | $51.48 | $12K | 25K |
| 2026-09-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2K | $50.71 | $94K | 25K |
| 2026-09-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 3K | $50.03 | $146K | 27K |
| 2026-09-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 5K | $2.48 | $12K | 30K |
| 2026-09-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 289 | $51.49 | $15K | 38K |
| 2026-09-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 2K | $50.72 | $111K | 38K |
| 2026-09-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 4K | $50.03 | $177K | 40K |
| 2026-09-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Exercise or conversion | 4K | $14.85 | $59K | 44K |
| 2026-08-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 1K | $59.35 | $82K | 40K |
| 2026-08-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 5K | $58.35 | $270K | 41K |
| 2026-08-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1K | $59.35 | $65K | 25K |
| 2026-08-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 4K | $58.37 | $228K | 26K |
| 2026-08-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 5K | $2.48 | $12K | 30K |
| 2026-08-04 | Derynck Mika K | Director | Sell | 159K | $60.21 | $9.6M | 0 |
| 2026-08-04 | Derynck Mika K | Director | Exercise or conversion | 20K | $22.47 | $460K | 159K |
| 2026-08-04 | Derynck Mika K | Director | Exercise or conversion | 23K | $14.85 | $347K | 138K |
| 2026-08-04 | Derynck Mika K | Director | Exercise or conversion | 28K | $25.28 | $697K | 115K |
| 2026-08-04 | Derynck Mika K | Director | Exercise or conversion | 87K | $2.48 | $217K | 87K |
| 2026-07-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 123 | $53.87 | $7K | 46K |
| 2026-07-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3K | $53.38 | $141K | 46K |
| 2026-07-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3K | $52.32 | $134K | 49K |
| 2026-07-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 369 | $51.48 | $19K | 51K |
| 2026-07-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 324 | $49.97 | $16K | 52K |
| 2026-07-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Exercise or conversion | 1K | $2.48 | $3K | 52K |
| 2026-07-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 63 | $53.92 | $3K | 25K |
| 2026-07-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2K | $53.42 | $117K | 25K |
| 2026-07-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2K | $52.39 | $108K | 27K |
| 2026-07-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 459 | $51.55 | $24K | 29K |
| 2026-07-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 231 | $50.05 | $12K | 30K |
| 2026-07-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 5K | $2.48 | $12K | 30K |
| 2026-07-06 | Kunkel Lori Anne | Director | Sell | 6K | $50.84 | $299K | 42K |
| 2026-07-06 | Kunkel Lori Anne | Director | Sell | 4K | $49.98 | $205K | 48K |
| 2026-06-22 | ORBIMED ADVISORS LLC | TenPercentOwner | Sell | 1K | $45.00 | $66K | 219K |
| 2026-06-22 | ORBIMED ADVISORS LLC | TenPercentOwner | Sell | 787K | $45.38 | $35.7M | 6.6M |
| 2026-06-22 | ORBIMED ADVISORS LLC | TenPercentOwner | Sell | 47K | $45.00 | $2.1M | 6.6M |
| 2026-06-22 | ORBIMED ADVISORS LLC | TenPercentOwner | Sell | 25K | $45.38 | $1.1M | 221K |
| 2026-06-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1K | $44.74 | $51K | 25K |
| 2026-06-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 3K | $43.87 | $114K | 26K |
| 2026-06-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1K | $42.83 | $54K | 29K |
| 2026-06-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 5K | $2.48 | $12K | 30K |
| 2026-06-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 1K | $42.79 | $59K | 56K |
| 2026-06-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3K | $43.86 | $149K | 52K |
| 2026-06-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 1K | $44.75 | $55K | 51K |
| 2026-06-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Exercise or conversion | 6K | $2.48 | $15K | 57K |
| 2026-06-15 | ORBIMED ADVISORS LLC | TenPercentOwner | Sell | 272K | $45.02 | $12.3M | 7.4M |
| 2026-06-15 | ORBIMED ADVISORS LLC | TenPercentOwner | Sell | 9K | $45.02 | $409K | 246K |
| 2026-06-05 | Kunkel Lori Anne | Director | Sell | 354 | $35.82 | $13K | 52K |
| 2026-06-05 | Kunkel Lori Anne | Director | Sell | 2K | $35.36 | $66K | 52K |
| 2026-06-05 | Kunkel Lori Anne | Director | Sell | 8K | $34.28 | $267K | 54K |
| 2026-05-18 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 223 | $41.21 | $9K | 25K |
| 2026-05-18 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1K | $40.25 | $52K | 25K |
| 2026-05-18 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 3K | $39.53 | $137K | 27K |
| 2026-05-18 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 5K | $2.48 | $12K | 30K |
| 2026-04-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2K | $48.06 | $117K | 25K |
| 2026-04-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2K | $47.39 | $115K | 27K |
| 2026-04-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 140 | $45.81 | $6K | 30K |
| 2026-04-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 5K | $2.48 | $12K | 30K |
| 2026-03-25 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 40K | $35.10 | $1.4M | 25K |
| 2026-03-25 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 40K | $2.48 | $99K | 65K |
| 2026-03-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 5K | $27.76 | $139K | 25K |
| 2026-03-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 5K | $2.48 | $12K | 30K |
| 2026-03-10 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 10K | $30.19 | $306K | 25K |
| 2026-03-10 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 10K | $2.48 | $25K | 35K |
| 2026-03-09 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 30K | $30.02 | $897K | 25K |
| 2026-03-09 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 30K | $2.48 | $74K | 55K |
| 2026-03-06 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 10K | $29.58 | $296K | 51K |
| 2026-02-17 | Heyman Richard A. | Director | Sell | 1K | $26.18 | $32K | 23K |
| 2026-02-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 45K | $26.17 | $1.2M | 25K |
| 2026-02-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Exercise or conversion | 45K | $2.48 | $112K | 70K |
| 2026-02-12 | Patel Anish | CHIEF OPERATING OFFICER | Grant | 20K | $0.00 | $0 | 20K |
| 2026-02-12 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Grant | 19K | $0.00 | $0 | 19K |
| 2026-02-12 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Grant | 25K | $0.00 | $0 | 61K |
| 2026-02-12 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Grant | 25K | $0.00 | $0 | 25K |
| 2026-02-06 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 5K | $29.04 | $145K | 740K |
| 2026-01-20 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 15K | $26.90 | $390K | 745K |
| 2026-01-20 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 5K | $26.37 | $145K | 760K |
| 2026-01-20 | Heyman Richard A. | Director | Sell | 718 | $26.96 | $19K | 24K |
| 2026-01-20 | Heyman Richard A. | Director | Sell | 512 | $26.46 | $14K | 25K |
| 2026-01-09 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 50K | $29.13 | $1.5M | 765K |
| 2026-01-09 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 41K | $24.90 | $1.0M | 815K |
| 2026-01-09 | Heyman Richard A. | Director | Sell | 4K | $25.00 | $107K | 25K |
| 2026-01-09 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 243 | $28.50 | $7K | 215K |
| 2026-01-09 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 48K | $27.98 | $1.3M | 215K |
| 2026-01-08 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 34K | $24.92 | $842K | 856K |
| 2026-01-08 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 8K | $20.13 | $151K | 890K |
| 2026-01-08 | Heyman Richard A. | Director | Sell | 8K | $25.04 | $201K | 29K |
| 2026-01-08 | Heyman Richard A. | Director | Sell | 2K | $25.00 | $41K | 26K |
| 2025-12-22 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Exercise or conversion | 13K | $2.48 | $32K | 36K |
| 2025-12-19 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 5K | $16.84 | $84K | 898K |
| 2025-12-17 | Kunkel Lori Anne | Director | Exercise or conversion | 16K | $1.12 | $18K | 31K |
| 2025-12-08 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 2K | $21.78 | $37K | 263K |
| 2025-12-08 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 5K | $20.76 | $103K | 265K |
| 2025-11-19 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 492 | $23.09 | $11K | 903K |
| 2025-11-19 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12K | $22.30 | $268K | 903K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON45 Form 144 notices on file for ELVN worth $91.4M at the prices reported; 4 in the last 90 days worth $4.0M. Latest: Collins Helen Louise filed on 2026-10-19 to sell 15,000 shares ($560K) from 2026-10-19.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-19 | Collins Helen LouiseDirector | 15K | $560K | 0.021% | 2026-10-19 | Jefferies LLC |
| 2026-10-01 | JEFFREY GARLANDDirector | 13K | $607K | 0.018% | 2026-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-17 | Hohl BenjaminOfficer | 12K | $591K | 0.016% | 2026-09-17 | Jefferies LLC |
| 2026-09-04 | Heyman Richard A.resigned from BOD | 38K | $2.3M | 0.062% | 2026-09-04 | Fidelity Brokerage Services LLC |
| 2026-08-04 | Derynck Mika KDirector | 159K | $9.2M | 0.224% | 2026-08-04 | Jefferies LLC |
| 2026-07-17 | Collins Helen LouiseOfficer | 15K | $763K | 0.021% | 2026-07-17 | Jefferies LLC |
| 2026-06-22 | OrbiMed Genesis Master Fund, L.P.Shareholder | 25K | $1.1M | 0.036% | 2026-06-22 | Jefferies LLC |
| 2026-06-22 | OrbiMed Private Investments VII, LPShareholder | 787K | $36.2M | 1.127% | 2026-06-22 | Jefferies LLC |
| 2026-06-22 | The Biotech Growth Trust PLCShareholder | 29K | $1.4M | 0.042% | 2026-06-22 | Jefferies LLC |
| 2026-06-17 | Hohl BenjaminOfficer | 18K | $768K | 0.030% | 2026-06-17 | Jefferies LLC |
| 2026-06-15 | The Biotech Growth Trust PLCShareholder | 10K | $434K | 0.015% | 2026-06-15 | Themis Trading LLC |
| 2026-06-15 | OrbiMed Private Investments VII, LPShareholder | 272K | $11.5M | 0.390% | 2026-06-15 | Themis Trading LLC |
| 2026-06-15 | OrbiMed Genesis Master Fund, L.P.Shareholder | 9K | $385K | 0.013% | 2026-06-15 | Themis Trading LLC |
| 2026-06-05 | Kunkel Lori AnneBoard Member | 20K | $710K | 0.033% | 2026-06-05 | Jefferies LLC |
| 2026-05-18 | Collins Helen LouiseOfficer | 15K | $620K | 0.025% | 2026-05-18 | Jefferies LLC |
| 2026-04-30 | Lyssikatos Joseph POfficer | 25K | $1.1M | 0.042% | 2026-04-30 | Jefferies LLC |
| 2026-03-31 | Lyssikatos Joseph POfficer | 25K | $915K | 0.042% | 2026-03-31 | Jefferies LLC |
| 2026-03-31 | ANDREW PHILLIPSFormer Director | 26K | $1.0M | 0.044% | 2026-03-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-25 | Collins Helen LouiseOfficer | 45K | $1.4M | 0.076% | 2026-03-25 | Jefferies LLC |
| 2026-03-24 | Patel AnishOfficer | 100K | $3.1M | 0.169% | 2026-03-24 | Jefferies LLC |
| 2026-03-09 | Collins Helen LouiseOfficer | 45K | $1.3M | 0.076% | 2026-03-09 | Jefferies LLC |
| 2026-03-06 | Hohl BenjaminOfficer | 10K | $293K | 0.017% | 2026-03-06 | Jefferies LLC |
| 2026-02-18 | Lyssikatos Joseph POfficer | 75K | $2.0M | 0.127% | 2026-02-18 | Jefferies LLC |
| 2026-02-17 | Kintz SamuelOfficer | 75K | $2.0M | 0.127% | 2026-02-17 | Jefferies LLC |
| 2026-02-17 | Heyman Richard A.Director | 1K | $33K | 0.002% | 2026-02-17 | Jefferies LLC |
| 2026-02-17 | Collins Helen LouiseOfficer | 45K | $1.2M | 0.076% | 2026-02-17 | Jefferies LLC |
| 2026-02-02 | ANDREW PHILLIPSFormer Director | 22K | $612K | 0.037% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-20 | Heyman Richard A.Director | 1K | $33K | 0.002% | 2026-01-20 | Jefferies LLC |
| 2026-01-09 | Lyssikatos Joseph POfficer | 75K | $1.7M | 0.127% | 2026-01-09 | Jefferies LLC |
| 2026-01-09 | Kintz SamuelOfficer | 75K | $1.7M | 0.127% | 2026-01-09 | Jefferies LLC |
| 2026-01-09 | Patel AnishOfficer | 48K | $1.1M | 0.082% | 2026-01-09 | Jefferies LLC |
| 2026-01-08 | Kintz SamuelOfficer | 83K | $1.3M | 0.140% | 2026-01-08 | Jefferies LLC |
| 2026-01-08 | Lyssikatos Joseph POfficer | 83K | $1.3M | 0.140% | 2026-01-08 | Jefferies LLC |
| 2026-01-08 | Heyman Richard A.Director | 2K | $25K | 0.003% | 2026-01-08 | Jefferies LLC |
| 2026-01-08 | Heyman Richard A.Director | 12K | $190K | 0.021% | 2026-01-08 | Jefferies LLC |
| 2025-12-19 | Lyssikatos Joseph POfficer | 5K | $83K | 0.008% | 2025-12-19 | Jefferies LLC |
| 2025-12-17 | Kintz SamuelOfficer | 5K | $85K | 0.008% | 2025-12-17 | Jefferies LLC |
| 2025-12-08 | Patel AnishOfficer | 7K | $145K | 0.011% | 2025-12-08 | Jefferies LLC |
| 2025-11-19 | Lyssikatos Joseph POfficer | 13K | $282K | 0.021% | 2025-11-19 | Jefferies LLC |
| 2025-11-17 | Kintz SamuelOfficer | 13K | $276K | 0.021% | 2025-11-17 | Jefferies LLC |
| 2025-10-20 | Lyssikatos Joseph POfficer | 13K | $268K | 0.021% | 2025-10-20 | Jefferies LLC |
| 2025-10-17 | Kintz SamuelOfficer | 13K | $272K | 0.021% | 2025-10-17 | Jefferies LLC |
| 2025-09-29 | Hohl BenjaminOfficer | 5K | $90K | 0.008% | 2025-09-29 | Jefferies LLC |
| 2025-09-19 | Lyssikatos Joseph POfficer | 13K | $249K | 0.021% | 2025-09-19 | Jefferies LLC |
| 2025-09-17 | Kintz SamuelOfficer | 13K | $230K | 0.021% | 2025-09-17 | Jefferies LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON14 holders report 5% or more of ELVN in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is FMR LLC at 15.0% of the class (10,713,540 shares), filed 2026-08-06 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 2 | BlackRock, Inc.parent holding company | 5.2M | 7.1% | 2026-09-30 |
| 2026-08-06 | 13G/Ano. 3 | FMR LLCparent holding company | 10.7M | 15.0% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 3 | Abigail P. Johnsonindividual | 10.7M | 15.0% | 2026-06-30 |
| 2026-06-24 | 13D/Ano. 5 | ORBIMED ADVISORS LLCinvestment adviser | 6.8M | 9.5% | 2026-06-22 |
| 2026-06-24 | 13D/Ano. 5 | ORBIMED CAPITAL GP VII LLCother entity | 6.6M | 9.2% | 2026-06-22 |
| 2026-06-24 | 13D/Ano. 5 | ORBIMED GENESIS GP LLCother entity | 219K | 0.3% | 2026-06-22 |
| 2026-06-24 | 13D/Ano. 5 | ORBIMED CAPITAL LLCinvestment adviser | 0 | 0.0% | 2026-06-22 |
| 2026-06-22 | 13G/Ano. 3 | Polar Capital Funds PLC - Biotechnology Fundother entity | 5.1M | 8.5% | 2026-03-31 |
| 2026-06-22 | 13G/Ano. 3 | Polar Capital LLPinvestment adviser | 5.1M | 8.5% | 2026-03-31 |
| 2026-06-22 | 13G/Ano. 3 | Polar Capital Holdings Plcparent holding company | 5.1M | 8.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Commodore Capital LPinvestment adviser, partnership | 4.8M | 7.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Michael Kramarzparent holding company, individual | 4.8M | 7.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Robert Egen Atkinsonparent holding company, individual | 4.8M | 7.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Commodore Capital Master LPpartnership | 4.8M | 7.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | VHCP Management III, LLCother entity | 1.7M | 2.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Venrock Healthcare Capital Partners EG, L.P.partnership | 1.7M | 2.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | VHCP Management EG, LLCother entity | 1.7M | 2.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Nimish Shahindividual | 1.7M | 2.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Bong Y. Kohindividual | 1.7M | 2.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Venrock Healthcare Capital Partners III, L.P.partnership | 1.7M | 2.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | VHCP Co-Investment Holdings III, LLCother entity | 1.7M | 2.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Kiselak Tomasparent holding company, individual | 1.9M | 3.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Peter Harwinparent holding company, individual | 1.9M | 3.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Fairmount Healthcare Fund II L.P.partnership | 1.9M | 3.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Fairmount Funds Management LLCinvestment adviser | 1.9M | 3.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Ryan Wilderparent holding company, individual | 3.3M | 5.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Vestal Point Capital, LPinvestment adviser, partnership | 3.3M | 5.4% | 2026-03-31 |
13F holders
Tracked managers holding ELVN at their latest 13F. JSON4 of the 30 tracked managers held ELVN at their latest 13F, $142.5M in total at quarter-end prices. Citadel Advisors is the largest at $105.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 2.1M | $105.0M | 0.01% | +325K |
| Millennium Management | 2026-06-30 | 411K | $20.9M | 0.01% | +66K |
| D. E. Shaw & Co. | 2026-06-30 | 306K | $15.5M | 0.01% | +112K |
| Two Sigma Investments | 2026-06-30 | 23K | $1.2M | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$70.3M of operating cash flow.
- Cash
- $135.5M
- Equity
- $895.1M
- Total assets
- $910.2M
- Shares outstanding
- 73,270,761
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$32.5M | n/a | -0.49 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$23.6M | n/a | -0.38 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$29.7M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$20.1M | n/a | -0.32 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$25.3M | n/a | -0.49 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$28.5M | n/a | -0.57 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$23.2M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$23.2M | n/a | -0.48 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$103.7M | -$70.3M | $158K | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$89.0M | -$73.2M | $44K | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$71.6M | -$61.3M | $149K | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$37.7M | -$32.1M | $612K | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$51.4M | -$46.8M | $12K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-28 from the cover page.
What this page is
Enliven Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Enliven Therapeutics (ELVN), SEC CIK 1672619, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-02.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-19.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-19.JSON and CSV
- Company record
- EDGAR filing index for CIK 1672619Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ELVN is sold short?
9,331,398 shares were held short at the 2026-10-15 settlement, 7.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ELVN's daily short volume?
On 2026-11-02, 242,095 of the 326,133 ELVN shares reported to FINRA were sold short, 74.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ELVN have fails to deliver?
The SEC's latest file shows 2,503 ELVN shares failed to deliver at settlement 2026-10-02. Fails are reported per settlement date and published twice a month with a lag.
Are ELVN insiders buying or selling?
Insiders at ELVN reported 13 open-market sells worth $2.2M in the last 90 days and no open-market buys. Latest filing: Collins Helen Louise (CHIEF MEDICAL OFFICER) on 2026-10-19.
Have ELVN insiders filed to sell?
45 Form 144 notices on file for ELVN worth $91.4M at the prices reported; 4 in the last 90 days worth $4.0M. Latest: Collins Helen Louise filed on 2026-10-19 to sell 15,000 shares ($560K) from 2026-10-19.
Who owns 5% or more of ELVN?
14 holders report 5% or more of ELVN in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is FMR LLC at 15.0% of the class (10,713,540 shares), filed 2026-08-06 for an event on 2026-06-30.
What did ELVN report last quarter?
In FY 2025 it generated -$70.3M of operating cash flow.
Which tracked 13F managers own ELVN?
4 of the 30 tracked 13F managers held ELVN shares at their latest filing, $142.5M in all. The largest: Ken Griffin's Citadel Advisors (2.1M shares, $105.0M), Izzy Englander's Millennium Management (411K shares, $20.9M), D. E. Shaw & Co. (306K shares, $15.5M), Two Sigma Investments (23K shares, $1.2M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.